Product Description
The use of radioisotopes is a (re)emerging approach for many drug development companies in the treatment of cancer. TransCode believes our TTX has the potential for efficient localized penetration of radioisotopes inside tumor cells. 64Cu-TTX-MC138 has potential benefits that include: PK profile that minimizes off-target exposure, maximizes high tumor uptake. Achieves localization, penetration, and persistence across tumor histologies while maximizing systemic clearance. Deeper tumor penetration to enable more homogeneous irradiation of tumor mass. Achieving the above enables use of off-target toxicity reducing short-range alpha emitters. In pre-clinical studies, delivery of 64Cu-TTX-MC138 to metastatic sites has already been demonstrated; a first-in-human microdosing study is anticipated in 1Q 2023. (Sourced from: https://www.transcodetherapeutics.com/other-candidates.html#/)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: TRANSCODE THERAPEUTICS
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|